Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels.

Immunol Res · 2022 · PMC9178219 · PMID 35679009

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Of note, when comparing severe and moderate patients with DXM treatment, HLA-DR expression was 21% lower in the severe group, although this result did not reach statistical significance (Fig. 2d ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.